NeuroBo appoints James P. Tursi, M.D. to Board effective Nov 1, 2023

MetaVia Inc.

Dr. Tursi brings 20 years pharma experience, currently EVP Global R&D at Endo International.
He will serve on the Nominating and Corporate Governance Committee; receives initial 25,000 RSUs and $40k annual cash retainer.
NeuroBo expects to file IND for DA-1726 (obesity) in coming months and start Phase 1a in H1 2024.
DA-1241 (NASH) is in a Phase 2a trial; Dr. Tursi's expertise targets large cardiometabolic markets.
Dr. Tursi's appointment strengthens board with deep R&D and regulatory background in drug development.

item 5.02 item 7.01 item 8.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

James P. Tursi, M.D.

Director

MTVA · MetaVia Inc.

Effective: 2023-11-01
Filed: November 6, 2023, 6:59 PM ET

On November 1, 2023, the Board of Directors (the “Board” ) of NeuroBo Pharmaceuticals, Inc., a Delaware corporation (the “Company” ), on the recommendation of the Nominating and Corporate Governance Committee of the Board (the “Nominating Committee” ), appointed James P. Tursi, M.D., effective immediately, to serve as a Class I director

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

James P. Tursi, M.D. was appointed as Director at MetaVia Inc..

Action: appointed
Role: Director

Exact text from the filing

On November 1, 2023, the Board of Directors (the “Board” ) of NeuroBo Pharmaceuticals, Inc., a Delaware corporation (the “Company” ), on the recommendation of the Nominating and Corporate Governance Committee of the Board (the “Nominating Committee” ), appointed James P. Tursi, M.D., effective immediately, to serve as a Class I director

View on SEC.gov

MetaVia Inc. filing history →

Source: SEC EDGAR

accession 0001558370-23-017666

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.